AMRX Q2 2024 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$702M+17.1% YoY

Gross Profit

$250M35.6% margin

Operating Income

$95M13.6% margin

Net Income

$6M0.9% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+6.5%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$29M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.5B

Stockholders' Equity

-$57M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$702M	$599M	+17.1%
Gross Profit	$250M	$220M	+13.6%
Operating Income	$95M	$80M	+19.2%
Net Income	$6M	$12M	-49.7%

Revenue Segments

Generics Segment

$427M80%

Amneal Specialty Pharma Segment

$104M20%